Company: STAA
Filing Date: 2025-09-05
Form Type: DEFA14A
Source: 0001193125-25-197213
Chunk: 0

Company: STAAR SURGICAL CO
Filing Date: 2025-09-05
Form: DEFA14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 
 14a-6(e)(2))                                                       |

| ☐ | Definitive Proxy Statement |

| ☐ | Definitive Additional Materials |

| ☒ | Soliciting Material under §240.14a-12 |

STAAR SURGICAL COMPANY (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box):

| ☒ | No fee required. |

| ☐ | Fee paid previously with preliminary materials. |

| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 
 14a-6(i)(1) and 0-11                                                           |

The Chief Executive Officer of STAAR Surgical Company (“STAAR”) sent the following email and enclosed Employee Q&A regarding compensation and benefits to STAAR employees on September 5, 2025: To: All Employees of STAAR Dear Team, It’s been a month since I shared the news with you that we entered into a definitive agreement for STAAR Surgical to be acquired by Alcon. I wanted to share an update on our progress and point you to additional resources with information about the merger transaction. First, I want to thank you all for your dedication to STAAR. We’re confident this transaction serves the best interest of STAAR team members, patients, customers, and shareholders, and I appreciate your efforts to minimize disruption and distraction from the transaction as much as possible. Until the transaction closes, both STAAR and Alcon must continue to operate as separate companies with business as usual – and I appreciate your efforts to continue to do your part to support our surgeons and patients. In the last 30 days, our team has been advancing key workstreams on the merger transaction. The transaction is subject to a number of closing conditions, including the adoption of the merger agreement by the holders of a majority of outstanding shares of STAAR common stock, as well as antitrust approvals in several countries. Last week, we filed with